Promise Bio

Executive Summary

Promise Bio is an Israeli AI-driven biotechnology company specializing in epiproteomics—the analysis of post-translational modifications (PTMs) from standard mass spectrometry data. Its cloud-based platform enables precision medicine for autoimmune diseases by facilitating biomarker discovery, patient stratification, and drug development support. Founded in 2020 and based in Tel Aviv, the company operates as a private platform-stage firm with 10-50 employees. By leveraging artificial intelligence to decode the 'epiproteome,' Promise Bio aims to uncover disease mechanisms and identify therapeutic targets that traditional genomics and proteomics miss. The platform's non-invasive, data-driven approach has the potential to improve diagnosis, monitoring, and treatment selection for complex autoimmune conditions, addressing a significant unmet need in immunology. Promise Bio's technology differentiates itself through its ability to analyze PTMs—key regulators of protein function—without requiring specialized equipment or reagents, making it accessible to existing mass spectrometry labs. The company's platform has the potential to accelerate drug development by providing deeper insights into disease biology and patient heterogeneity. As precision medicine gains traction, Promise Bio is well-positioned to partner with pharmaceutical companies and research institutions seeking to enhance their autoimmune pipelines. However, as an early-stage company with undisclosed funding and no commercial products, execution risk remains. Success will depend on platform validation, customer adoption, and securing strategic collaborations to drive revenue and scale.

Upcoming Catalysts (preview)

• Q3 2026Commercial launch of epiproteomics platform70% success
• Q4 2026First major partnership with a pharmaceutical company50% success
• Q2 2026Publication of peer-reviewed validation study in autoimmune disease80% success